Αρχική World News Zantac Contains A Cancer-Causing Chemical And Now Breast Cancer Patients Are Suing

Zantac Contains A Cancer-Causing Chemical And Now Breast Cancer Patients Are Suing

Zantac is a popular, over-the-counter heartburn medication whose generic name is ranitidine. The Food and Drug Administration (FDA) announced in September of 2019 that they found that Zantac contains low levels of a probable human carcinogen called N-nitrosodimethylamine, or NDMA.However, the FDA isn’t recalling the medication. Instead, they issued a warning, saying, “Patients taking prescription ranitidine who wish to discontinue use should talk to their health care professional about other treatment options.”There has, however, been a voluntary recall of over-the-counter (OTC) ranitidine tablets (both 75 mg and 150 mg) labeled by Walgreens, Walmart, and Rite-Aid and manufactured by Apotex Corp. And some pharmacies, like Walgreens and CVS, are pulling the drugs from their shelves.Photo: NBC 6
NDMA is classified as a probable carcinogen and environmental contaminant that’s found in water and foods. Last year, several recalls for blood pressure medications went out after NDMA was found in them. The FDA is currently working with industry regulators and partners to determine where the contamination began for Zantac.The FDA says that the amounts of NDMA they found aren’t much higher than the amounts found in common foods.Photo: NBC 6Zantac has been sold over the counter since 1995 and was the first drug in history to rack up $1 billion in sales. The generic name for the drug is ranitidine, and some of the names it’s sold under are: Wal-Zan 75, Heartburn Relief (ranitidine), Acid Reducer (ranitidine), Acid Control (ranitidine), Wal-Zan 150, Zantac Maximum Strength, and Zantac 75.
Ranitidine lowers the amount of acid that the stomach produces, and is available in both OTC and prescription forms. The prescription version is stronger and is approved for more uses than just preventing and relieving heartburn, such as the treatment of GERD (gastroesophageal reflux disease) and the treatment and prevention of ulcers.Photo: NBC 6Shortly after the FDA announced the warning about Zantac, two breast cancer patients in South Florida filed lawsuits against Sanofi, the maker of Zantac.Joseph Galimidi’s attorneys filed the first lawsuit. He claims that his breast cancer diagnosis was due to Zantac. He’s a rabbi in Adventura.“There are millions of people that take Zantac and ranitidine yearly and they’ve been exposed to this extremely potent carcinogen,” Galimidi’s attorney, Yitzhak Levin, told NBC Miami. “As a result they are potentially able to develop cancer as a result of being exposed.”
Photo: NBC 6Nancy Lopez has been taking Zantac for acid reflux since she was 15. She was diagnosed with breast cancer for the first time in 2012, and then diagnosed again last year. The single mom works as a nanny and has been through chemo, radiation, and many surgeries.“I know there are a lot of single moms out there with breast cancer and taking this medication they don’t know,” she told NBC Miami. “And somebody got to say something and I decided to be the first one.”Photo: NBC 6
“This is not about money. This is about saving people,” Lopez said. “If I can save one, everything is gonna be worth it for me. It doesn’t matter what I’ve been through. That’s not a problem. I just don’t want other people to go through what I went through.”Sanofi released a statement to CNBC, saying, “Sanofi takes patient safety seriously, and we are committed to working with the FDA.” They also said that Zantac OTC (over the counter) “has been around for over a decade and meets all the specified safety requirements for use in the OTC market.”Photo: NBC 6At the time of this writing, at least two class-action lawsuits have been filed against Sanofi and Boehringer Ingelheim for intentionally hiding the cancer risk in Zantac.There are other similar drugs to Zantac on the market. Talk to a healthcare professional if you are concerned and want to switch medications.Learn more in this video.
Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal,...

The UK Government’s spending review: Time to invest in the future of cancer care

This autumn, the chancellor Rishi Sunak will go to Parliament and set out the UK Government’s spending priorities in the Comprehensive Spending Review...

FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma

On 14 October 2020, the US Food and Drug Administration (FDA) extended the approval of pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme Corp.) for the...

31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During the Pandemic

The COVID-19 pandemic has been a scary and difficult thing for most of the world, and it’s important to keep safety protocols in place...

For Esophageal Cancer, Immunotherapy Likely to Play Larger Role

October 19, 2020, by NCI Staff An esophagram using barium contrast shows the esophagus. Credit: iStock Immunotherapy may become part of early treatment for some people with...

Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is Feasible

Targeted therapy recommendations can be made based on the molecular profiles of tumour samples from patients with metastatic malignant mesothelioma (MM) according to findings...